Literature DB >> 26803187

Acute esophagitis for patients with local-regional advanced non small cell lung cancer treated with concurrent chemoradiotherapy.

Yi Pan1, Carsten Brink2, Marianne Knap3, Azza A Khalil3, Christa H Nyhus4, Tine McCulloch5, Bente Holm6, Yi-long Wu7, Tine Schytte8, Olfred Hansen9.   

Abstract

PURPOSE: Esophagitis is common in patients treated with definitive radiotherapy for local-regional advanced non small cell lung cancer (NSCLC). The purpose of this study was to estimate the dose-effect relationship using clinical and dosimetric parameters in patients receiving intensity modulated radiotherapy (IMRT) and concomitant chemotherapy (CCT).
METHODS: Between 2009 and 2013, 117 patients with stages IIB-IIIB NSCLC were treated in a multicenter randomized phase II trial with 2 cycles of induction chemotherapy followed by IMRT and CCT. The esophagitis was prospectively scored using the Common Toxicity Criteria 3.0. Clinical and dosimetric variables were analyzed for the correlation with grade ⩾2 esophagitis through logistic regression.
RESULTS: Grade 2 esophagitis was experienced by 31 (27%). All models including gender, institution, a dosimetric parameter and a position parameter were significantly associated with esophagitis. The two models using the relative esophagus volume irradiated above 40 Gy (V40, OR=2.18/10% volume) or the length of esophagus irradiated above 40 Gy (L40, OR=4.03/5 cm) were optimal. The upper part of esophagus was more sensitive and females experienced more toxicity than men.
CONCLUSION: V40 and L40 were most effective dosimetric predictors of grade ⩾2 esophagitis. The upper part of esophagus was more sensitive.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Acute esophagitis; Concurrent chemoradiotherapy; IMRT; Non small cell lung cancer

Mesh:

Year:  2016        PMID: 26803187     DOI: 10.1016/j.radonc.2016.01.007

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  6 in total

1.  Risk factors for esophagitis after hypofractionated palliative (chemo) radiotherapy for non-small cell lung cancer.

Authors:  Carsten Nieder; Kristian S Imingen; Bård Mannsåker; Rosalba Yobuta; Ellinor Haukland
Journal:  Radiat Oncol       Date:  2020-05-01       Impact factor: 3.481

2.  Account for the Full Extent of Esophagus Motion in Radiation Therapy Planning: A Preliminary Study of the IRV of the Esophagus.

Authors:  Aihui Feng; Hengle Gu; Hua Chen; Yan Shao; Hao Wang; Yanhua Duan; Ying Huang; Tao Zhou; Zhiyong Xu
Journal:  Front Oncol       Date:  2021-11-25       Impact factor: 6.244

3.  Radiation-Induced Esophagitis in Non-Small-Cell Lung Cancer Patients: Voxel-Based Analysis and NTCP Modeling.

Authors:  Serena Monti; Ting Xu; Radhe Mohan; Zhongxing Liao; Giuseppe Palma; Laura Cella
Journal:  Cancers (Basel)       Date:  2022-04-05       Impact factor: 6.639

4.  A systematic review and meta-analysis of treatment-related toxicities of curative and palliative radiation therapy in non-small cell lung cancer.

Authors:  M Or; B Liu; J Lam; S Vinod; W Xuan; R Yeghiaian-Alvandi; E Hau
Journal:  Sci Rep       Date:  2021-03-15       Impact factor: 4.996

5.  Clinical, dosimetric, and position factors for radiation-induced acute esophagitis in intensity-modulated (chemo)radiotherapy for locally advanced non-small-cell lung cancer.

Authors:  Jin Huang; Tianyu He; Ronghui Yang; Tianlong Ji; Guang Li
Journal:  Onco Targets Ther       Date:  2018-09-21       Impact factor: 4.147

6.  Evaluation of Epigallocatechin-3-Gallate as a Radioprotective Agent During Radiotherapy of Lung Cancer Patients: A 5-Year Survival Analysis of a Phase 2 Study.

Authors:  Wanqi Zhu; Yalan Zhao; Shuyu Zhang; Xiaolin Li; Ligang Xing; Hanxi Zhao; Jinming Yu
Journal:  Front Oncol       Date:  2021-06-10       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.